We report on a patient having McCune-Albright syndrome (MAS) associated with non-autoimmune hyperthyroidism associated with thyrotoxic crisis. Polyostotic fibrous dysplasia developed at age 8, and café-au-lait pigmentation was noted on the skin. At age 18, he developed hyperthyroidism with multiple adenomatous changes. The hyperthyroidism had been controlled with an antithyroid drug, but the antithyroid medication was discontinued by the patient at age 23. One year later, thyrotoxic crisis developed with fever, convulsions and loss of consciousness. Thyroid function tests showed serum concentrations of free T4 of 5.1 ng/dl, and serum TSH of <0.1 μU/ml. Serum thyroglobulin concentrations were markedly increased (1,280 ng/ml). Three major thyroid-related autoantibodies (TSH receptor antibody, antithyroglobulin, and antimicrosomal antibodies) were not detected in serum. Serum GH concentrations were increased, and not suppressed by the glucose tolerance test, but increased paradoxically by TRH. The thyrotoxic crisis was ameliorated by treatment with a β-adrenergic receptor-blocking agent, glucocoroticoid, iodine, antithyroid drug, and antibiotics. The cause of thyroidal defect in our patient is not considered to be autoimmune hyperthyroidism, but hyperthyroidism due to constitutive activation of Gsα by inhibition of its GTPase. This paper describes, as far as we know, the first case of MAS associated with thyrotoxic crisis. Because hyperthyroidism in this patient recurred quickly after discontinuation of the antithyroid drug, the mode of treatment for MAS-associated hyperthyroidism appears to be total surgical ablation or repetitive radioiodine therapy.

Keywords:
McCune-Albright syndrome, Thyrotoxic crisis, Non-autoimmune hyperthyroidism, Growth hormone hypersecretion
1.
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L: GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature 1989;340:692–696.
2.
Lyons J, Landis CA, Harsh G, Vallar L, Gruneward K, Feichtinger H, Duh OY, Clark OH, Kawasaki E, Bourne HR, McCormick F: Two G protein oncogenes in human endocrine tumors. Science 19990;249:655–659.
3.
Weinstein LS, Shenker A, Gejman PV, Marino MJ, Friedman E, Spiegel AM: Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688–1695.
4.
Schwindinger WF, Francomono CA, Levine MA: Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992;89:5152–5156.
5.
Shenker A, Weinstein LS, Sweet DE, Spiegel AM: An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994;79:750–755.
6.
Malchoff CD, Readon G, MacDillivray DC, Yamase H, Rogol AD, Malchoff DM: An unusual presentation of McCune-Albright syndrome comfirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab 1994;78:803–806.
7.
McCune DJ: Osteitis fibrosa cystica; the case of a nine-year-old girl who also exibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 1936;52:743–747.
8.
Albright F, Butler AM, Hampton AO, Smith P: Syndrome characterized by osteitits fibrosa disseminata, area of pigmentation and endocrine dysfunction, with precocious puberty in females: Report of five cases. N Engl J Med 1937;216:727–746.
9.
Dotsch J, Kiess W, Hanze J, Repp R, Ludecke D, Blum WF, Rascher W: Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. J Clin Endocrinol Metab 1996;81:3839–3842.
10.
Hamilton CR Jr, Maloff F: Unusual types of hyperthyroidism. Medicine 1973;52:195–215.
11.
Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohmann LA: Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989;68:1148–1154.
12.
Chanson P, Dib A, Viscot A, Dermone PJ: McCune-Albright syndrome and acromegaly: Clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994;131:229–234.
13.
Ringel MD, Schwindinger WF, Levine MA: Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996;75:171–184.
14.
Feuillan PP, Shawker T, Rose SR, Jones J, Jeevanram RK, Nisula BC: Thyroid abnormalities in the McCune-Albright syndrome: Ultrasonography and hormonal studies. J Clin Endocrinol Metab 1990;71:1596–1601.
15.
Shantharaj S, Gilman S, Maurer HS, Rosenthal IM: Hyperthyroidism in an infant with McCune-Albright syndrome: Report of a case with myeloid metaplasia. J Pediatr 1972;80:275–278.
16.
Mastrorakos G, Mitsiades NS, Doufas AG, Koutras DA: Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 1997;7:433–439.
17.
Gessel A, Freissmuth M, Czech T, Matula C, Hainfellner JA, Buchfelder M, Vierhapper H: Growth hormone-prolactin-thyrotropin-secreting pituitary adenoma in atypical McCune-Albright syndrome with functionally normal Gsα protein. J Clin Endocrinol Metab 1994;79:1128–1134.
18.
Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G: Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993;365:649–651.
19.
Sakane S, Takamatsu J, Yoshida S, Takeda K, Ohsawa N, Katayama S, Kuma K, Kohno Y, Hosoya T: Clinical features and characteristics of thyroid function; in Lee M, Koh CS, Eastman CJ, Nagataki S (eds): Graves’ disease patients with multiple adenomatous hyperplasia. Prog Thyroid. Seoul, Korea Medical Publishing Company, 1989, pp 403–406.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.